INmune Bio (INMB) Q4 2025 Earnings Transcript
INmune Bio’s Q4 2025 earnings transcript reported net loss attributable to common shareholders of about $45.9M, up from $42.1M a year earlier. R&D fell to $20.7M from $33.2M, while G&A rose to $10.3M from $9.5M. The company recorded a $16.5M impairment after an Alzheimer’s trial missed its endpoint, raised ~$17.4M via registered direct and $10.1M via ATM, and ended with $24.8M cash, funding operations through Q1 2027.
How this was made
The 30-second read
Why it matters
Key near-term trading drivers are (1) advanced CORDStrom regulatory submission readiness with a targeted mid-summer 2026 U.K. MAA, (2) a full $16.5M impairment tied to the Alzheimer’s trial missing its primary endpoint, and (3) equity financing extending runway into Q1 2027—together shaping probability-weighted valuation and dilution expectations.
Market read
The call reframes the story toward late-stage regulatory execution and funding runway while acknowledging a material impairment from an Alzheimer’s clinical miss.
What to watch
Equity dilution risk from the registered direct and ATM raises may offset runway benefits; also, priority review voucher expectations can be uncertain versus actual FDA decision timing.
Background
INmune Bio’s Q4/FY2025 earnings transcript covers financials, cash runway, and pipeline execution across CORDStrom (RDEB), XPro (Alzheimer’s), and INKmune (mCRPC).
Ticker impact
INmune Bio reported Q4 results and detailed CORDStrom regulatory submission timelines, XPro Phase II/Phase III path, and a $16.5M impairment tied to Alzheimer’s trial failure.
Likely modest-to-moderate volatility: positive on CORDStrom regulatory progress and runway extension, offset by impairment and ongoing Alzheimer’s uncertainty.
The transcript contains multiple discrete catalysts (MAA/BLA timing, impairment, equity raises, cash runway) that can re-rate probability-weighted value, but it’s still pre-approval and includes negative trial outcome context.
Market effects
Reinforces the biotech market’s focus on regulatory/CMC readiness and cash runway over single-trial headline outcomes.
U.K./EU filing cadence (MAA/EMA later in 2026) may influence sentiment among European small-cap biotech investors.
FDA alignment and potential priority review voucher narrative can affect broader rare-disease/biologics risk appetite.
Counterpoint
CORDStrom progress may already be priced; the impairment and Alzheimer’s endpoint miss could dominate until Phase III readouts de-risk the franchise.
Key entities
- programCORDStrom
MSC-based therapy platform for RDEB; transcript highlights batch-to-batch consistency, potency assays, and finalizing U.K./U.S. regulatory submissions.
- clinical_programXPro (MINDFuL)
Phase II Alzheimer’s trial did not meet primary endpoint, but totality of data supported FDA alignment to proceed to Phase III.
- clinical_programINKmune
Phase II metastatic castration-resistant prostate cancer study completed ahead of schedule and under budget, meeting primary and two secondary endpoints.
- regulatory_featurePriority Review Voucher
Management expects a priority review voucher for the CORDStrom BLA application based on orphan/rare pediatric designations.
